These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 19491086)

  • 1. Feasibility study of docetaxel with cyclophosphamide as adjuvant chemotherapy for Japanese breast cancer patients.
    Takabatake D; Taira N; Hara F; Sien T; Kiyoto S; Takashima S; Aogi K; Ohsumi S; Doihara H; Takashima S
    Jpn J Clin Oncol; 2009 Aug; 39(8):478-83. PubMed ID: 19491086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
    Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II trial of adjuvant dose-dense docetaxel/epirubicin/cyclophosphamide (TEC) in stage II and III breast cancer.
    Burdette-Radoux S; Wood ME; Olin JJ; Laughlin RS; Crocker AM; Ashikaga T; Muss HB
    Breast J; 2007; 13(3):274-80. PubMed ID: 17461902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
    Nabholtz JM; Cantin J; Chang J; Guevin R; Patel R; Tkaczuk K; Vodvarka P; Lindsay MA; Reese D; Riva A; Mackey J
    Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer.
    Cousin S; Le Rhun E; Mailliez A; Fournier C; Bonneterre J
    Bull Cancer; 2012; 99(7-8):75-80. PubMed ID: 22713627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.
    Jones S; Holmes FA; O'Shaughnessy J; Blum JL; Vukelja SJ; McIntyre KJ; Pippen JE; Bordelon JH; Kirby RL; Sandbach J; Hyman WJ; Richards DA; Mennel RG; Boehm KA; Meyer WG; Asmar L; Mackey D; Riedel S; Muss H; Savin MA
    J Clin Oncol; 2009 Mar; 27(8):1177-83. PubMed ID: 19204201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: results of a feasibility study.
    Cardoso F; Ferreira Filho AF; Crown J; Dolci S; Paesmans M; Riva A; Di Leo A; Piccart MJ
    Anticancer Res; 2001; 21(1B):789-95. PubMed ID: 11299845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TAXTOX - a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009.
    Eckhoff L; Nielsen M; Moeller S; Knoop A
    Acta Oncol; 2011 Oct; 50(7):1075-82. PubMed ID: 21824038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
    Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
    Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer.
    Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
    Clin Breast Cancer; 2006 Feb; 6(6):511-7. PubMed ID: 16595034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
    Roché H; Fumoleau P; Spielmann M; Canon JL; Delozier T; Serin D; Symann M; Kerbrat P; Soulié P; Eichler F; Viens P; Monnier A; Vindevoghel A; Campone M; Goudier MJ; Bonneterre J; Ferrero JM; Martin AL; Genève J; Asselain B
    J Clin Oncol; 2006 Dec; 24(36):5664-71. PubMed ID: 17116941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant docetaxel for high-risk, node-negative breast cancer.
    Martín M; Seguí MA; Antón A; Ruiz A; Ramos M; Adrover E; Aranda I; Rodríguez-Lescure A; Grosse R; Calvo L; Barnadas A; Isla D; Martinez del Prado P; Ruiz Borrego M; Zaluski J; Arcusa A; Muñoz M; López Vega JM; Mel JR; Munarriz B; Llorca C; Jara C; Alba E; Florián J; Li J; López García-Asenjo JA; Sáez A; Rios MJ; Almenar S; Peiró G; Lluch A;
    N Engl J Med; 2010 Dec; 363(23):2200-10. PubMed ID: 21121833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.
    Yu JL; Chan K; Kurin M; Pasetka M; Kiss A; Sridhar SS; Warner E
    Breast J; 2015; 21(6):658-64. PubMed ID: 26387577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The feasibility of FEC (75) as adjuvant chemotherapy for Japanese breast cancer patients].
    Kim SJ; Taguchi T; Miyoshi Y; Tanji Y; Tamaki Y; Noguchi S
    Gan To Kagaku Ryoho; 2005 Nov; 32(12):1919-23. PubMed ID: 16282727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.
    Jones SE; Savin MA; Holmes FA; O'Shaughnessy JA; Blum JL; Vukelja S; McIntyre KJ; Pippen JE; Bordelon JH; Kirby R; Sandbach J; Hyman WJ; Khandelwal P; Negron AG; Richards DA; Anthony SP; Mennel RG; Boehm KA; Meyer WG; Asmar L
    J Clin Oncol; 2006 Dec; 24(34):5381-7. PubMed ID: 17135639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer.
    Margolin S; Bengtsson NO; Carlsson L; Edlund P; Hellstrøm M; Karlsson P; Lidbrink E; Linderholm B; Lindman H; Malmström P; Pettersson Skøld D; Søderberg M; Villman K; Bergh J;
    Acta Oncol; 2011 Jan; 50(1):35-41. PubMed ID: 21174610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicity of dose-dense docetaxel followed by doxorubicin with cyclophosphamide as adjuvant therapy for breast cancer in a phase II study.
    Lambert-Falls R; Modugno S
    Clin Breast Cancer; 2007 Aug; 7(9):697-704. PubMed ID: 17919350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting.
    Lyman GH; Dale DC; Tomita D; Whittaker S; Crawford J
    Breast Cancer Res Treat; 2013 Jun; 139(3):863-72. PubMed ID: 23771731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
    Yardley D; Burris H; Peacock N; Raefsky E; Melnik M; Inhorn R; Shipley D; Hainsworth J
    Breast Cancer Res Treat; 2010 Sep; 123(2):471-5. PubMed ID: 20658263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer.
    Loesch D; Greco FA; Senzer NN; Burris HA; Hainsworth JD; Jones S; Vukelja SJ; Sandbach J; Holmes F; Sedlacek S; Pippen J; Lindquist D; McIntyre K; Blum JL; Modiano MR; Boehm KA; Zhan F; Asmar L; Robert N
    J Clin Oncol; 2010 Jun; 28(18):2958-65. PubMed ID: 20479419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.